CURE® Spring 2021 Issue

A gynecologic oncologist who has spent her career helping patients during their cancer journeys goes a step further to educate women on how to advocate for themselves and possibly prevent cancer before it occurs.

Sophisticated analyses can predict which gut microbiome profile may lead to better outcomes to immunotherapy for patients with advanced melanoma.

Luckily, obtaining a second opinion has become easier with advances in telehealth and other virtual technologies, which allow patients to share their medical records and test results with physicians and pathologists to potentially improve treatment plans.

Clinical trials are often the key to advancements in treating ovarian cancer. As part of its “Speaking Out” video series, CURE® spoke with Dr. Debra Richardson about what patients should know about joining a trial.

As part of the “Speaking Out” video series, CURE® spoke with Dr. Laura M. Kulik about the basics of liver cancer, highlighting the need for a multidisciplinary approach to care.

Channeling optimism during your cancer journey isn’t just about living longer — it’s about living better.

The gut microbiome plays an important role in how patients may respond to cancer treatments, and researchers are learning more about ways to alter it to benefit treatment outcomes.

Second opinions may enhance your treatment plan or even change your course.

Patients with non-small cell lung cancer and a KRAS G12C genetic mutation may benefit from treatment with an inhibitor targeting that mutation, although more research is needed to learn why more patients are not responding to the drug.

An expert spoke with CURE® about the FDA’s recent approval of Libtayo to treat patients with locally advanced basal cell carcinoma who previously had only one therapy option for locally advanced disease.

The biggest fear for many patients, according to an expert from The University of Texas MD Anderson Cancer Center, is when they hear that myeloma, for most patients, is not curable. However, she notes that every few years patient survival is increasing.

The combination of Cabometyx (cabozantinib) plus Opdivo (nivolumab) “is certainly going to become one of the new standards of care” for the treatment of advanced renal cell carcinoma now that the regimen is approved, according to an expert from the Dana-Farber Cancer Institute.

Patients treated with Imbruvica plus TG-1101 had an overall response rate of 83% compared with 65% in those treated with Imbruvica alone.

There are two myths that patients with cancer believe when it comes to being health advocates. Here, a panel of experts look to dispel those myths to help patients become better advocates.

A caregiver recalls how an unexpected side effect of her daughter’s breast cancer treatment has caused her to experience feelings of helpless anger.

A cancer survivor pens an ode to her port that has made her journey much less stressful.